cysteamine has been researched along with Pancreatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buya, M; Chen, J; Dong, X; Guo, Q; Kang, M; Lu, W; Qin, W; Wu, Y; Zheng, W | 1 |
| Fujisawa, T; Gahl, WA; Joshi, BH; Patel, PS; Puri, RK; Rubin, B; Suzuki, A | 1 |
2 other study(ies) available for cysteamine and Pancreatic Neoplasms
| Article | Year |
|---|---|
VNN1, a potential biomarker for pancreatic cancer-associated new-onset diabetes, aggravates paraneoplastic islet dysfunction by increasing oxidative stress.
Topics: Adenocarcinoma; Aged; Amidohydrolases; Animals; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cysteamine; Diabetes Mellitus; Female; Glutathione; GPI-Linked Proteins; Humans; Islets of Langerhans; Mice; Middle Aged; Oxidative Stress; Pancreatic Neoplasms; Paraneoplastic Syndromes; PPAR gamma | 2016 |
Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Cysteamine; Disease Models, Animal; Enzyme Inhibitors; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured | 2012 |